Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

Keyphrases

• Multiple Sclerosis 100%
• Relapsing-remitting multiple Sclerosis 100%
• Treatment Switch 100%
• Relapsing-remitting MS 80%
• Anti-CD20 60%
• High-efficacy DMT 60%
• Logistic Regression Model 40%
• Multivariable Logistic Regression 40%
• Protective Factors 40%
• Disease-modifying Therapy 40%
• Related Disorders 40%
• MS Patients 40%
• Switcher 40%
• Data Extraction 20%
• Disease Course 20%
• Natalizumab 20%
• Disease Activity 20%
• Rituximab 20%
• Therapy Switch 20%
• Clinical Activity 20%
• Progressive multiple Sclerosis 20%
• Clinical Relapse 20%
• Ocrelizumab 20%
• Alemtuzumab 20%
• Treatment Exposure 20%

Immunology and Microbiology

• Multiple Sclerosis 100%
• CD20 75%
• Rituximab 25%
• Secondary Progressive Multiple Sclerosis 25%
• Natalizumab 25%
• Data Extraction 25%
• Ocrelizumab 25%
• Alemtuzumab 25%

Biochemistry, Genetics and Molecular Biology

• CD20 100%
• Cross Sectional Study 33%
• Data Extraction 33%
• Rituximab 33%
• Natalizumab 33%
• Ocrelizumab 33%
• Alemtuzumab 33%